HC Wainwright Issues Pessimistic Forecast for ACTU Earnings

Actuate Therapeutics, Inc. (NASDAQ:ACTU) – HC Wainwright dropped their FY2030 EPS estimates for shares of Actuate Therapeutics in a report released on Monday, May 18th. HC Wainwright analyst S. Ramakanth now forecasts that the company will post earnings per share of $1.24 for the year, down from their previous forecast of $1.35. HC Wainwright has a “Buy” rating and a $15.00 price objective on the stock. The consensus estimate for Actuate Therapeutics’ current full-year earnings is ($0.80) per share.

Actuate Therapeutics (NASDAQ:ACTU) last issued its quarterly earnings results on Thursday, May 14th. The company reported ($0.24) EPS for the quarter, missing the consensus estimate of ($0.23) by ($0.01).

Several other equities analysts have also recently commented on ACTU. Weiss Ratings reissued a “sell (e+)” rating on shares of Actuate Therapeutics in a research report on Friday, March 27th. Wall Street Zen raised shares of Actuate Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, April 4th. Two research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Actuate Therapeutics has an average rating of “Hold” and an average price target of $17.50.

Actuate Therapeutics Stock Down 7.3%

Shares of ACTU stock opened at $2.43 on Tuesday. Actuate Therapeutics has a 52 week low of $1.58 and a 52 week high of $11.99. The stock has a market capitalization of $58.15 million, a PE ratio of -2.51 and a beta of 0.92. The firm has a 50 day moving average of $2.55 and a two-hundred day moving average of $4.62.

Institutional Investors Weigh In On Actuate Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Sfmg LLC raised its holdings in shares of Actuate Therapeutics by 17.6% in the fourth quarter. Sfmg LLC now owns 20,000 shares of the company’s stock valued at $122,000 after buying an additional 3,000 shares during the last quarter. Barclays PLC raised its holdings in shares of Actuate Therapeutics by 68.6% in the fourth quarter. Barclays PLC now owns 14,946 shares of the company’s stock valued at $91,000 after buying an additional 6,081 shares during the last quarter. State Street Corp raised its holdings in shares of Actuate Therapeutics by 12.8% in the fourth quarter. State Street Corp now owns 56,290 shares of the company’s stock valued at $344,000 after buying an additional 6,395 shares during the last quarter. ABS Direct Equity Fund LLC purchased a new stake in shares of Actuate Therapeutics in the fourth quarter valued at about $40,000. Finally, Wells Fargo & Company MN raised its holdings in shares of Actuate Therapeutics by 48.8% in the fourth quarter. Wells Fargo & Company MN now owns 20,146 shares of the company’s stock valued at $123,000 after buying an additional 6,604 shares during the last quarter.

About Actuate Therapeutics

Actuate Therapeutics (NASDAQ: ACTU) is a clinical-stage oncology company focused on the discovery and development of targeted therapies designed to address key drivers of tumor growth and survival. Headquartered in South San Francisco, California, the company applies a precision medicine approach to identify novel molecular targets and develop small-molecule agents that have the potential to improve outcomes for patients with difficult-to-treat cancers.

The company’s lead asset, atuveciclib, is a selective, oral CDK9 inhibitor being evaluated in a Phase 1 clinical trial for patients with acute myeloid leukemia and advanced solid tumors.